ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO015

AKI Associated with Fenofibrate

Session Information

Category: Acute Kidney Injury

  • 101 AKI: Epidemiology, Risk Factors, and Prevention

Authors

  • Na, Jeonggu, Gyeongsang National University Changwon Hospital, Changwon-si, Korea (the Republic of)
  • Park, Dong Jun, Gyeongsang National University Changwon Hospital, Changwon-si, Korea (the Republic of)
  • Lee, Tae won, Gyeongsang National University Hospital, Changwon-si, Gyeongsangnam-do, Korea (the Republic of)
  • Bae, Eunjin, Gyeongsang National University Changwon Hospital, Changwon-si, Korea (the Republic of)
  • Cho, Junhyeong, Change-won Gyungsang National University, Chang-won, Korea (the Republic of)
  • Jang, Ha nee, Gyeongsang National Univ. Hospital, Jinju, Korea (the Republic of)
  • Cho, Hyun Seop, Gyeongsang National University Hospital, Changwon-si, Gyeongsangnam-do, Korea (the Republic of)
  • Chang, Se-Ho, Gyeongsang National University Hospital, Changwon-si, Gyeongsangnam-do, Korea (the Republic of)
Background

Fenofibrate was widely used to treat hypertriglyceridemia for many years. It was well known that fenofibrate can trigger acute kidney injury. We studied to investigate the relationship between acute kidney injury and fenofibrate.

Methods

We retrospectively evaluated the medical records of patients to start fenofibrate prescription for hypertriglyceridemia from January 2010 to December 2018 in the tertiary hospital. We reviewed their underlying disease, laboratory findings, dose of fenofibrate, duration of fenofibrate, and concomitant drug use. We did the effort to find factors related to acute kidney injury by fenofibrate.

Results

Total 169 patients were included. The mean age was 63.3 ± 11.5 years old. 40 of 169 patients had acute kidney injury(n=40, 23.6%), and 17 patients had chronic kidney disease(n=17, 10.0%). Patients with diabetes mellitus showed significantly increased risk of acute kidney injury without diabetes mellitus (29.0% vs 15.9%, p=0.04). We found significant correlation between hypertension and acute kidney injury. (30.8% vs 12.3%, p=0.006). Patients with concomitant use of RAS blockers showed significantly decreased renal function compared with non-user of RAS blockers(31.4% vs 10.9%, p=0.002). In subgroup analysis, patients with chronic kidney disease have statistically significant risk of acute kidney injury by fenofibrate (47.1% vs 21.1%, p=0.017). Mean estimated glomerular filtration rate(eGFR) by MDRD was each 28.4 ± 12.1 mL/min/1.73m2 in chronic kidney disease group and 66.2 ± 20.3 mL/min/1.73m2 in non-chronic kidney disease group.

Conclusion

Diabetes mellitus, hypertension, and concomitant use of RAS blocker have a statistically significant association with acute kidney injury by fenofibrate in our study. And patients with chronic kidney disease have greater risk in acute kidney injury by fenofibrate.